Clinical Course and Risk Factors for Mortality from COVID-19 in Patients with Hematological Malignancies

Sánchez-Pina, José María; Rodríguez, Mario; Quismondo, Nerea Castro; Manso, Rodrigo Gil; Colmenares, R.; Alos, Daniel Gil; Paciello, Mari Liz; Zafra, Denis; García‐Sánchez, Carmen; Villegas, Carolina; Cuéllar, Clara; Carreño, Gonzalo; Zamanillo, Irene; Poza, María; Íñiguez, R.; Gutierrez, Xabier; Alonso, Rafael; Rodríguez, Antonia; Folgueira, María Dolores; Delgado, Rafaël; Ferrari, José Miguel; Lizasoaín, Manuel; Aguado, José María; Ayala, Rosa; Martínez‐López, Joaquín; Calbacho, María

doi:10.2139/ssrn.3608097

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These variations are different from case to case and level of the disease severity. Neutropenia has been previously reported in about 35%-85% of patients and was the most common blood count abnormality [10][11][12] . The main objective of this research was to evaluate the variations of CBC levels of COVID-19 patients with the disease severity.…”

Section: ~ 147 ~mentioning

confidence: 94%

“…Neutrophils are the most characteristic cell type among the white blood cells and are an important component of the immune system. Except for clinical symptoms and pulmonary computed tomography (CT) findings, most confirmed COVID-19 patients revealed laboratory fluctuations in different serological parameters, including renal and liver function tests, coagulation parameters, and inflammatory, biochemical and hemocytometric parameters [10,11] . To show the prognosis and hyper inflammation state, a combination of laboratory tests has been evaluated.…”

Section: ~ 147 ~mentioning

confidence: 99%

“…The combination of the various tests includes platelet-tolymphocyte (PLR) and neutrophils to lymphocyte ratio (NLR). COVID-19 leads to variation in the hematological parameters, including lymphocytes, white blood cells, platelets, neutrophils, etc [11][12][13] . These variations are different from case to case and level of the disease severity.…”

Section: ~ 147 ~mentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of hematological parameters in covid-19 patients in district Hapur

Kansal¹,

Joon²,

Kumar³

et al. 2021

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

The coronavirus disease (COVID-19) sparked from Wuhan city of China and rapidly developed into a pandemic. The critically ill patients of COVID-19 exhibit features of hyper inflammation, and the particular blood tests may be rewarding for prognosis. Our aim was to investigate the CBC, which includes total leukocyte, lymphocytes and granulocytes count, Hemoglobin, MCV, MCH, MCHC, RBCs and Platelet count, NLR etc. The current study was conducted to conclude the alteration in blood parameters and their association with the severity and mortality of COVID-19 patients. Methods: An observational cross-sectional study was conducted retrospectively, a total of 100 COVID-19 positive patients were examined: 50 were mild, 25 were moderate, 10 were severe, and 15 were critically diseased patients. Unfortunately, we recorded 6 deaths among the critical group. The overall mean age observed in our study was 48.94 years, where the mean age for critical individuals was 62.12 ± 14.35 years. Results: A significant association between the disease severity and elevation in blood parameters were observed. The total WBC's and Neutrophils count were significantly decreased (p value<0.001). The lymphocyte count was increased in critical patients (1.40 × 109 /L) compared to mild patients (1.92 × 109 /L) (p = 0.28). Conclusion:These blood parameters could be used as a suitable biomarker for the prognosis and severity of COVID-19. Evaluating novel hemograms, NLR can aid clinicians to identify potentially severe cases at early stages, initiate effective management in time, and conduct early triage which may reduce the overall mortality of COVID-19 patients.

show abstract

Section: ~ 147 ~mentioning

confidence: 94%

Section: ~ 147 ~mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of hematological parameters in covid-19 patients in district Hapur

Kansal¹,

Joon²,

Kumar³

et al. 2021

Int. J. Clin. Diagn. Pathol.

View full text Add to dashboard Cite

show abstract

“…2 Furthermore, the risk of adverse outcomes associated with COVID-19 (eg, death or requiring ventilation) has not been found to be higher in recent large studies of patients with cancer in US, European, and hematological malignancy cohorts; however, the data are still evolving. [3][4][5][6] Another challenge for the comprehensive modeling of RRs in cancer treatment settings is the myriad combinations of treatment modalities, schedules, clinic visit patterns, and associations between specific drugs and infection susceptibility as well as the receipt of multimodality treatment plans among many patients. Hartman et al 1 have considered the risks of several discrete categories of treatment, but the complexities of cancer care make it almost impossible to tailor these assumptions to all cancer patients.…”

mentioning

confidence: 99%

To Treat or Not to Treat—Balancing Benefits and Risks of Treatment Delay Among Patients With Cancer During the COVID-19 Pandemic

Garrett‐Mayer

Rini

2020

JAMA Oncol

View full text Add to dashboard Cite

Decisions regarding the initiation of cancer therapy have become increasingly complex in the era of coronavirus disease 2019 . Health care professionals and patients must balance the benefits and risks of immediate treatment for cancer with the potential subsequent increases in the risk of COVID-19 and its associated complications, including death. Unlike approaches that triage cancer treatment using a tiered approach, Hartman et al 1 have developed a web-based comprehensive model (Onc-COVID) to estimate the risk of delaying the initiation of cancer treatment for an individual patient with cancer. This model

show abstract

Clinical Course and Risk Factors for Mortality from COVID-19 in Patients with Hematological Malignancies

Cited by 2 publications

References 0 publications

Evaluation of hematological parameters in covid-19 patients in district Hapur

Evaluation of hematological parameters in covid-19 patients in district Hapur

To Treat or Not to Treat—Balancing Benefits and Risks of Treatment Delay Among Patients With Cancer During the COVID-19 Pandemic

Contact Info

Product

Resources

About